Table 2.

Risk Factors for ESKD after Pediatric Liver Transplantation: Results of Univariable and Multivariable Cox Regression

Variable	Unadjusted Hazard Ratio for ESKD* (95% conf int)	p value	Adjusted Hazard Ratio for ESKD* (95% conf int)	p value
Age at liver transplant
0 to <5 years	Reference		Reference
5 to <10 years	2.64 (1.66–4.19)	<0.001	2.75 (1.72–4.40)	<0.001
10 to <15 years	4.30 (2.83–6.52)	<0.001	3.93 (2.57–6.00)	<0.001
15 to 18 years	5.48 (3.67–8.18)	<0.001	4.94 (3.29–7.42)	<0.001
Male sex	1.43 (1.05–1.94)	0.023	1.44 (1.05–1.96)	0.022
Black vs non-black race	1.42 (0.99–2.05)	0.059	1.46 (1.01–2.13)	0.046
Era of transplant
1990–1994	Reference		Reference
1995–1999	0.63 (0.42–0.94)	0.024	0.67 (0.44–1.00)	0.050
2000–2004	0.83 (0.51–1.36)	0.467	0.87 (0.53–1.42)	0.573
2005–2010	0.96 (0.49–1.88)	0.905	1.11 (0.56–2.17)	0.765
Liver disease with potential primary kidney involvement**	1.41 (0.97–2.04)	0.070	1.30 (0.89–1.91)	0.175
Hepatitis B	3.09 (1.52–6.29)	0.002	2.25 (1.10–4.62)	0.027
Hepatitis C	4.16 (2.12–8.16)	<0.001	2.79 (1.40–5.58)	0.004
eGFR pre-LT <60 vs ≥60, ml/min/1.73m2	2.31 (1.63–3.28)	<0.001	2.37 (1.66–3.37)	<0.001
Liver re-transplant***	2.78 (1.96–3.94)	<0.001	2.67 (1.88–3.80)	<0.001

^*Multivariable Cox regression for ESKD is censored at death and adjusted for other variables in table

^**Alagilles syndrome, alpha-1 anti-trypsin deficiency, congenital hepatic fibrosis, cystic fibrosis, glycogen storage diseases, primary hyperoxaluria, tyrosinemia, Wilsons disease

^***Liver re-transplant is treated as a time-varying covariate